| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4645875
Max Phase: Preclinical
Molecular Formula: C37H47Br2N7O5
Molecular Weight: 829.63
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COc1ccccc1C1CCN(C(=O)N[C@H](Cc2cc(Br)c(O)c(Br)c2)C(=O)N[C@@H](CCCCN)C(=O)N2CCN(c3ccncc3)CC2)CC1
Standard InChI: InChI=1S/C37H47Br2N7O5/c1-51-33-8-3-2-6-28(33)26-11-16-46(17-12-26)37(50)43-32(24-25-22-29(38)34(47)30(39)23-25)35(48)42-31(7-4-5-13-40)36(49)45-20-18-44(19-21-45)27-9-14-41-15-10-27/h2-3,6,8-10,14-15,22-23,26,31-32,47H,4-5,7,11-13,16-21,24,40H2,1H3,(H,42,48)(H,43,50)/t31-,32+/m0/s1
Standard InChI Key: CVPWNBYUSUFFDB-AJQTZOPKSA-N
Associated Targets(Human)
Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 193 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 829.63 | Molecular Weight (Monoisotopic): 827.2005 | AlogP: 4.78 | #Rotatable Bonds: 13 |
| Polar Surface Area: 153.36 | Molecular Species: BASE | HBA: 8 | HBD: 4 |
| #RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 6.75 | CX Basic pKa: 10.20 | CX LogP: 2.82 | CX LogD: 2.08 |
| Aromatic Rings: 3 | Heavy Atoms: 51 | QED Weighted: 0.18 | Np Likeness Score: -0.57 |
References
| 1. Dubowchik GM, Conway CM, Xin AW.. (2020) Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success., 63 (13): [PMID:32058712] [10.1021/acs.jmedchem.9b01810] |
Source
Source(1):